Issue Highlights

In the Study of Biologic and Immunomodulator Naive Patients in Crohn ’s Disease (SONIC) trial, patients with moderate-to-severe Crohn’s disease (CD) who were treated with infliximab in combination with azathioprine (AZA) and were naïve to both drugs achieved higher corticosteroid-free remission and endoscopic healing than either drug alone at Week 26. To determi ne if thiopurines impact the pharmacokinetics of infliximab or works synergistically with infliximab, Colombel and colleagues1 performed a post hoc analysis of study data from 206 CD patients (97 on infliximab monotherapy and 109 on combination therapy) with available serum samples collected at Week 30.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Issue highlights Source Type: research